Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1TV5

Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor

Summary for 1TV5
Entry DOI10.2210/pdb1tv5/pdb
DescriptorDihydroorotate dehydrogenase homolog, mitochondrial, SULFATE ION, (2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide, ... (7 entities in total)
Functional Keywordsalpha-beta barrel; tim barrel, oxidoreductase
Biological sourcePlasmodium falciparum (malaria parasite P. falciparum)
Cellular locationMitochondrion inner membrane (By similarity); Single-pass membrane protein (Potential): Q08210
Total number of polymer chains1
Total formula weight51939.95
Authors
Hurt, D.E.,Widom, J.,Clardy, J. (deposition date: 2004-06-27, release date: 2005-09-06, Last modification date: 2024-10-09)
Primary citationHurt, D.E.,Widom, J.,Clardy, J.
Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor.
Acta Crystallogr.,Sect.D, 62:312-323, 2006
Cited by
PubMed Abstract: Membrane-associated dihydroorotate dehydrogenase (DHODH) is an antimalarial therapeutic target without an effective inhibitor. Studies on human DHODH (HsDHODH) led to a structural mechanistic model in which respiratory quinones bind in a tunnel formed by the highly variable N-terminus that leads to the flavin mononucleotide-binding site. The therapeutic agents leflunomide (Arava) and brequinar sodium inhibit HsDHODH by binding in this tunnel. Plasmodium falciparum DHODH (PfDHODH) and HsDHODH have markedly different sensitivities to the two drugs. To understand the structural basis of this differential sensitivity and begin a structure-based drug-design cycle for PfDHODH inhibitors, the three-dimensional structure (2.4 Angstroms, R = 20.1%) of PfDHODH bound to the active metabolite of leflunomide was determined by X-ray crystallography. Comparison of the structures of HsDHODH and PfDHODH reveals a completely different binding mode for the same inhibitor in these two catalytically identical enzymes and explains the previously observed species-specific preferential binding. Because no effective inhibitors have been described for PfDHODH, this structure provides critical insight for the design of potential antimalarials.
PubMed: 16510978
DOI: 10.1107/S0907444905042642
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.4 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon